Here are 14 recent drug shortages and discontinuations, according to FDA drug supply databases:
- Acetaminophen; oxycodone hydrochloride tablet: Multiple strengths of Percocet were discontinued Nov. 3 due to the end of manufacturing.
- Atazanavir sulfate; cobicistat tablet: Evotaz was discontinued Nov. 3. Global manufacturing is expected to cease beginning in April.
- Everolimus tablet: The 2 mg, 3 mg and 5 mg strengths were discontinued Nov. 3.
- Lasmiditan succinate tablet: All 50 mg and 100 mg presentations of Reyvow were discontinued Nov. 3 as a business decision.
- Scopolamine transdermal system: Discontinued Nov. 3.
- Phenobarbital tablet: All strengths — including 16.2 mg, 32.4 mg, 64.8 mg and 97.2 mg — were discontinued Oct. 31.
- Moxifloxacin injection: The 400 mg/250 mL formulation was discontinued Oct. 29.
- Pramlintide acetate injection: SymlinPen 60 and 120 were discontinued Oct. 27.
- Busulfan injection: The 6 mg/mL presentation was discontinued Oct. 24.
- Insulin glargine injection: The Basaglar U-100 Tempo Pen was discontinued Oct. 24.
- Insulin lispro injection: The Humalog U-100 Tempo Pen was discontinued Oct. 24.
- Insulin lispro-aabc injection: The Lyumjev U-100 Tempo Pen and sample were discontinued Oct. 24.
- Lorazepam injection: Currently in shortage due to increased demand.
